Printer Friendly

Advaxis awarded orphan drug designation for ADXS-HPV for treating invasive cervical cancer.

M2 PHARMA-May 2, 2014-Advaxis awarded orphan drug designation for ADXS-HPV for treating invasive cervical cancer


Cancer immunotherapies company Advaxis (NasdaqCM:ADXS) revealed on Thursday the receipt of orphan drug designation from the US Food and Drug Administration (FDA) for ADXS-HPV for the treatment of Stage II-IV invasive cervical cancer.

This Orphan Drug Designation was granted by the US Food and Drug Administration's (FDA) Office of Orphan Products Development (OOPD).

The company added that ADXS-HPV is an immunotherapy that is designed to target cells expressing the HPV gene E7. Expression of the E7 gene from high-risk HPV variants is responsible for the transformation of infected cells into dysplastic and malignant tissues. Eliminating these cells can eliminate the dysplasia or malignancy.

ADXS-HPV is designed to infect antigen-presenting cells and direct them to generate a powerful, cellular immune response to HPV E7, concluded the company.

((Comments on this story may be sent to

COPYRIGHT 2014 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:May 2, 2014
Previous Article:Alcobra wins second US patent for Metadoxine for cognitive disorders.
Next Article:Miraculins advances talks over Scout DS distribution in China.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters